<DOC>
	<DOCNO>NCT00933543</DOCNO>
	<brief_summary>The purpose trial study efficacy safety Visonac PDT patient 9 35 year old AktiliteÂ® CL512 . Patients randomized Visonac vehicle cream without occlusion red light ( dose : 37J/cm2 )</brief_summary>
	<brief_title>Efficacy Safety Study With Visonac Photodynamic Therapy ( PDT )</brief_title>
	<detailed_description>Double blind , prospective , randomize , stratify , placebo-controlled , multi-center study patient moderate severe acne vulgaris . Patients facial severity grade 3 4 Investigator 's Global Assessment ( IGA ) scale include . Each patient classify accord age two age group 9 12 year 13 35 year randomize either Visonac vehicle cream within age group . All patient receive 4 treatment 2 week apart ( week 0 , 2 ,4 6 week ) . Efficacy evaluation do treatment 12 week first treatment . Safety evaluation perform treatment visit 12 week first treatment . Photographs patient take treatment first last treatment visit , 12 week first treatment . Blood sample draw 3 visit ; pre-treatment visit , one week first treatment one week last treatment visit .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Female male patient , 9 year age moderate severe facial acne vulgaris ( IGA score 34 ) . Female patient surgically sterile , premenstrual , postmenopausal , abstinent , willing use adequate mean contraception include birth control pill , barrier method spermicide least 14 day prior T1 . Patients use birth control pill must use product dose least 6 month must agree stay product dose additional 6 month . Fitzpatrick skin type I VI . Patients 20 100 inflammatory lesion ( papule , pustule , nodule ) face . Patients 30 120 noninflammatory lesion ( open close comedo ) face . Patients 2 nodular lesion face . Signed verify informed consent form . For subject age 18 , assent form conjunction inform consent form , sign verified parent/guardian . Patients present follow include study : Patient investigator sub investigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol . Patients unlikely comply protocol , e.g. , mental condition render patient unable understand nature , scope , possible consequence clinical study , uncooperative attitude unlikelihood complete study ( e.g. , drug alcohol abuse ) . Female patient use oral contraceptive , use product dose within last 6 month agree stay product dose duration study . Pregnancy Patients undergo testosterone systemic hormonal treatment . Patients use hormonal contraceptive solely control acne . Known allergy MAL , similar PDT compound , excipients cream . Patients porphyria . Patients cutaneous photosensitivity . Participation clinical study either concurrently within last 30 day , T1 . Patients washout period topical treatment e.g. , topical BPOs , retinoids antibiotic , acne less 14 day , T1 . Medicated cleanser may use washout period stop treatment . Patients washout period oral antibiotic treatment acne less 1 month , T1 . Patients washout period oral isotretinoin le 6 month , T1 . Patients beard facial hair might interfere study assessment . Patients melanoma dysplastic nevus treatment area . Exposure ultraviolet radiation ( UVB phototherapy , sun tan salon ) within last 30 day . Exposure PDT within 12 week T1 .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Acne Vulgaris</keyword>
	<keyword>Moderate severe</keyword>
</DOC>